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Abstract 
Pancreatic neuroendocrine neoplasms (pNEN) account for less than 5% of all pancreatic 
neoplasms and genetic association studies on susceptibility to the disease are limited. We 
sought to identify possible overlap of genetic susceptibility loci between pancreatic ductal 
adenocarcinoma (PDAC) and pNEN; therefore, PDAC susceptibility variants (n=23) from 
Caucasian genome-wide association studies (GWAS) were genotyped in 369 pNEN cases and 
3,277 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium to evaluate the 
odds associated with pNEN risk, disease onset and tumor characteristics. Main effect analyses 
showed four PDAC susceptibility variants – rs9854771, rs1561927, rs9543325 and rs10919791 
to be associated with pNEN risk. Subsequently, only associations with rs9543325, rs10919791 
and rs1561927 were noteworthy with false positive report probability (FPRP) tests. Stratified 
analyses considering age at onset (50 year threshold), showed rs2736098, rs16986825 and 
rs9854771 to be associated with risk of developing pNEN at a younger age. Stratified analyses 
also showed some SNPs to be associated with different degrees of tumor grade, metastatic 
potential and functionality. Our results identify known GWAS PDAC susceptibility loci, which 
may also be involved in sporadic pNEN etiology and suggest that some genetic mechanisms 
governing pathogenesis of these two entities may be similar, with few of these loci being more 
influential in younger cases or tumor subtypes.  
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Summary: This study identifies an overlap of susceptibility loci between PDAC and pNEN which 
may provide insights on potentially useful markers for risk stratification and tumor 
characterization among healthy individuals and pNEN patients respectively.  
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Introduction 
Pancreatic neuroendocrine neoplasms (pNEN) arise from islet cells and comprise less than 5% 
of all new pancreatic neoplasms (1). Heterogeneous in tumor behavior and clinical symptoms, 
pNENs account for 10% of neuroendocrine tumors and have a 5-year mortality rate of 60% 
(1,2). Compared to the more common exocrine pancreatic ductal adenocarcinoma (PDAC), 
pNENs are characterized by a rather ‘silent’ clinical course and generally present at a relatively 
earlier age (median age at diagnosis 53 to 60 years, and 72 years for PDAC) (1). Majority (40-
90%) of pNENs are non-functional (i.e. do not secrete hormones that cause systemic effects) 
thus constituting a clinical and prognostic challenge for physicians. Surgical resection is 
currently the primary curative therapy option for both malignancies, however, most patients 
unfortunately exhibit unresectable tumors at diagnosis (3), stressing the need for improved risk 
stratification and timely diagnostic biomarkers. Familial clustering observed in population-
based studies among PDAC and other cancer patients provide evidence of an inherited basis for 
sporadic pNEN (1). Although there is no clear link between environmental exposures and risk of 
developing pNEN, an overlap of risk factors in PDAC and pNENs is likely (4). Increased interest in 
these neoplasms has become evident in the last decade, but despite this, molecular 
understanding of pNENs is still insufficient to drive clinical interventions. Recent exome and 
whole genome sequencing studies describing the genetic basis of pNENs among Caucasians 
(5,6) have implicated somatic mutations in four core pathways: activation of mTOR signaling, 
DNA damage repair, chromatin modification and altered telomere length in tumorigenesis. 
Genome wide association (GWAS) or candidate gene or pathway studies investigating the 
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etiology of pNENs have been reasonably limited by small sample size, when compared to PDAC 
for which 23 common risk variants have so far been identified through GWAS or studies 
focusing on genes situated in well-known pleiotropic regions (7–11). Based on the rationale 
that known common genetic susceptibility loci for sporadic PDAC may also modify the risk of 
developing pNEN, we genotyped 369 pNEN cases from a retrospectively enrolled population 
within the PANDoRA consortium and compared genotype frequencies of all known PDAC GWAS 
susceptibility variants to over 3,200 control subjects from the same consortium. We tested their 
possible association with overall sporadic pNEN risk and within pNEN subgroups. 
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Materials and methods 
Selection of subjects and polymorphisms: Demographic characteristics subjects within the 
PANDoRA consortium have been described previously (12) although the number of 
neuroendocrine cases within PANDoRA has increased since that publication. Written informed 
consent and biospecimens (blood, tissue or genomic DNA) were obtained for all subjects and 
ethical approval for the PANDoRA study protocol received from the Ethics commission of the 
Medical Faculty Heidelberg. Only sporadic (non-familial) pNEN cases not associated with 
genetic syndromes such as multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindau 
syndrome (VHL), von Recklinghausen disease (neurofibromatosis NF-1), and tuberous sclerosis 
complex (TSC) were used in this study. Twenty-three (23) single nucleotide polymorphisms 
(SNPs) reaching genome-wide significance and suggestive levels (up to 5 x 10-7) were selected 
from GWAS publications in PDAC among Caucasians (7–10). pNEN tumors were classified 
according to the World Health Organization 2010 classification system (13).   
 
Genotyping and quality control: SNPs were genotyped in 369 pNEN cases and 3,277 controls 
using TaqMan allelic discrimination (Applied Biosystems) and KASPar (LGC Genomics) assays 
according to manufacturers’ instructions. Post-PCR allelic discrimination was done on the 
7900HT Real-Time PCR system (Life Technologies) and data analyzed using the affiliated SDS 
software (v.2.3). Internal replicates (7% of all samples) and negative controls were included to 
assess the fidelity of genotype calls. Deviation from Hardy Weinberg equilibrium (HWE) was 
checked using the Pearson’s 2 test. 
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Statistical analyses: We evaluated associations (odds ratios (OR) and 95% confidence intervals 
(CI)) between SNPs and pNEN risk using unconditional multivariate logistic regression in STATA 
v.11 (StataCorp LP). Tests were done using a codominant inheritance model, with adjustment 
for potential confounding variables - age, geographical origin and gender. We used a nominal 
significance threshold (p<0.05) since the selected SNPs were based on prior evidence of their 
association with pancreatic cancer. Noteworthiness of SNP associations with p<0.05 were 
tested using the Bayesian false positive report probability (FPRP) test which takes the observed 
P-value, statistical power of the test, and prior probabilities for the associations into account 
(14). All selected SNPs bore a high prior possibility of being associated with pNEN risk ( = 0.2) 
as recommended by Wacholder and colleagues (14), and only SNP associations with p<0.05 and 
0.2 were considered ‘noteworthy’. To evaluate the effect of SNPs on pNEN onset, we first 
performed a case-only analysis comparing genotype distributions among cases (>50 years) with 
their younger counterparts (≤50 y ars) while adjusting for gender and geographical origin. We 
also compared genetic associations from three additional models: cases ≤50 years versus 
controls of all ages (EOP1), cases >50 years versus controls of all ages (TOP), and cases up to 50 
years versus controls up to 50 years (EOP2). Associations between SNPs and tumor grade and 
stage were estimated by case-only analyses. For tumor stage, we compared stage IV tumors 
versus all other tumors (stage I, IIa, IIb, IIIa, IIIb) based on European Neuroendocrine Tumor 
Society (ENETS) classification system (15) and for grade, we compared well differentiated 
tumors (grade 1 and 2) versus poorly differentiated tumors (grade 3) based on the World 
Health Organization (WHO)/ENETS guidelines (16). Tumor functional status (e.g. insulinoma, 
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gastrinomas, etc) was available for 54% of all cases in this study, out of which 62% were non-
functioning. We compared genotype frequencies of all SNPs in the latter with functioning 
tumors.  
 
Microarray data screening: To gain additional insight to the transcriptomic profiles of these 
gene regions in human pancreatic islet cells, we explored expression profiling data from the 
Gene Expression Omnibus (GEO) database (Accession number GSE43795); this study 
characterized mRNA and microRNA expression profiles in solid-pseudopapillary neoplasms of 
pancreas (n=14), ductal adenocarcinoma (n=6), pancreatic neuroendocrine tumors (n=6) and 
non-neoplastic pancreatic tissue samples (n=5) (17). Results were downloaded in text format 
and GEO2R queries (http://www.ncbi.nlm.nih.gov/geo/geo2r/) applied to assess differentially-
expressed genes in pNEN compared to non-neoplastic pancreas tissue samples. GEO2R is an R 
programming language-based dataset analysis tool that compares two or more groups of 
samples under the same experimental conditions and analyzes almost any GEO series (18). P 
values were adjusted to correct for false-positives due to multiple testing using Benjamini and 
Hochberg false discov ry rate method and genes that met the cut-off criteria of Padjusted < 0.05 
and |logFC| > 1.0 were screened out as differentially-expressed genes. 
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Results 
Baseline characteristics of the study population are summarized in table I. The median age at 
diagnosis in this study was 57 years, congruent with previous literature reports. Genotypes for 
most SNPs, except rs505922 (P = 0.04) were distributed in accordance to Hardy-Weinberg 
equilibrium (HWE) among controls. Duplicated samples showed genotyping concordance rate 
of 99.6%. Genotyping data for those subjects with genotyping completion rates below 75% (n = 
35) were excluded from all statistical analyses.  
 
Overall pNEN risk analyses:  Minor allele frequencies, genotype distributions, risk estimates 
(odds ratios (OR) and 95% confidence intervals (CI)) of all polymorphisms investigated in this 
study are summarized in table II. rs9543325 was associated with higher risk of pNEN (OR 1.63, 
95% CI (1.10-2.47), Phom = 0.02). rs10919791, rs1561927 and rs9854771 were associated with 
lower risk of pNEN (OR 0.65, 95% CI (0.46-0.93), Phet = 0.02; OR 0.71, 95% CI (0.55-0.92), Phet = 
0.01 and OR 0.76, 95% CI (0.58-0.99), Phet = 0.04 respectively). Subsequent testing of these 
findings using false positive report probability (FPRP) with a prior of 0.2 showed that only 
associations with rs10919791 (FPRP = 0.13), rs9543325 (FPRP = 0.15) and rs1561927 (FPRP = 
0.07) were noteworthy. The association with rs9854771 failed the noteworthiness test (FPRP = 
0.25). 
 
Stratified analyses based on age at pNEN onset: With stratification according to age at disease 
onset (≤50 years vs. >50 years) among successfully genotyped pNEN cases, we observed 
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significant differences between genotype groups for rs16986825 (ZNRF) (OR 2.67, 95% CI (1.57-
4.55), Phet = 0.0003 and OR 2.27, 95% CI (1.37-3.77), P = 0.002 in the recessive model); 
rs2736098 (TERT) (OR 3.71, 95% CI (1.36-10.10), Phom = 0.01; and rs9854771 (TP63) (OR 1.85, 
95% CI (1.11-3.10), Phet = 0.02 and OR 1.69 , 95% CI (1.04-2.75), P = 0.03 in the recessive model 
(table III). FPRP tests were similarly applied using a prior probability of 0.2 and associations 
between early pNEN onset and rs16986825 (FPRP < 0.01 in both models), rs2736098 (FPRP = 
0.08), and rs9854771 (FPRP = 0.14), were noteworthy. For rs9854771, our observed association 
for the recessive model was not noteworthy (FPRP = 0.22). Since pNENs are diagnosed roughly 
10 years earlier than PDAC, we also performed the same stratified analyses with threshold at 40 
years, and only the TERT SNPs (rs2736098 and rs2853677) were significantly associated with 
higher risk of developing pNEN at 40 years or younger, albeit with extremely small group sizes 
(results not shown). Results from alternative analyses of disease onset using three additional 
models: cases ≤50 years versus controls of all ages (EOP1), cases >50 years versus controls of all 
ages (TOP), and cases up to 50 years versus controls up to 50 years (EOP2) are shown in 
supplementary table I.  
 
Stratified analyses based on tumor characteristics (grade, stage and functional status): With 
stratification based on disease grade, rs10919791 and rs16986825 were associated with well 
differentiated pNEN tumors (OR 5.11, 95% CI (1.13 - 23.14), P = 0.03 and OR 7.44, 95% CI (1.09 - 
50.5), P = 0.04 respectively). rs1561927, rs9854771 and rs351365 were also associated with 
tumors with nodal metastasis (i.e. advanced stage) (OR 2.39, 95% CI (1.18 - 4.85), P = 0.02; OR 
0.46, 95% CI (0.24 - 0.88), P = 0.02; and OR 4.62, 95% CI (1.16 - 18.38), P = 0.03) respectively. 
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However, only the association between rs9854771 and stage appeared reliable, considering 
that the size of genotype groups was much smaller for other SNPs. FPRP tests applied using a 
prior probability of 0.2 showed the association between tumor grade and rs10919791 (FPRP = 
0.19) to be noteworthy. For rs16986825, the association was not noteworthy (FPRP > 0.20). 
Regarding tumor stage, associations with rs1561927, rs9854771 and rs351365 (recessive model 
only) (FPRP=0.11, 0.16 and 0.19 respectively) were noteworthy. Two variants rs7310409 
(HNF1A) and rs1517037 (GRP) also appeared to be associated with tumor functional status (OR 
0.36, 95% CI (0.16-0.79), P = 0.01 and OR 0.37, 95% CI (0.16-0.85), P = 0.02 respectively (table 
III). Both associations were noteworthy at the 0.2 threshold (FPRP < 0.08). Associations 
between all 23 SNPs and tumor characteristics are shown i  supplementary table II.  
 
Differentially-expressed genes based on microarray data screening: Reasoning that the 
additional gene expression profiles of all 26 genes harboring or located close to the SNPs 
investigated in this study would amplify our ability to identify relevant underlying biological 
processes, we screened a GEO superseries dataset including 6 pNEN, 5 healthy pancreas 
(controls) and 6 ductal adenocarcinoma tissue samples. Based on the inclusion criteria of 
Padjusted < 0.05 and |logFC| > 1.0, five of these genes – nuclear receptor subfamily 5 group A 
member 2 (NR5A2), v-myc avian myelocytomatosis viral oncogene homolog (MYC), Krüppel-like 
factor (KLF) 5 (KLF5) and chymotrypsinogen genes, CTRB1 and CTRB2 were under expressed in 
pNEN compared to normal pancreas tissue (table V). Supplementary table III shows expression 
data for all 23 SNPs. Our analyses are based on only a few samples, therefore caution should be 
applied in the interpretation of these results. 
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Discussion 
By investigating known GWAS PDAC susceptibility loci (MAF≥5%), our study has identified the 
possible role of these loci in the risk of developing pNEN. Combined with gene expression 
analyses, we report for the first time, few loci which may also be involved in genetic 
mechanisms influencing pNEN tumorigenesis, age at onset and tumor characteristics. These 
findings confirm that some susceptibility loci are shared by both entities. Interestingly, most 
known environmental risk factors associated with increased pNEN risk are also associated with 
PDAC risk (4). Although rarity and lack of predictive biomarkers for early-stage diagnosis or risk 
stratification of healthy individuals in both entities are two common features of these 
neoplasms, understanding their molecular mechanisms remains essential and advantageous. It 
is common albeit controversial knowledge that pancreatic ductal cells are ‘potential facultative 
stem cells’ capable of being reprogrammed into cells that closely resemble islet cells in vivo 
(19,20). Whether the shared genetic susceptibility is due to the origin of both these tumor 
types from a common pluripotent precursor cell, or a phenomenon linked with the reported 
capacity of islet cells to transdifferentiate to ductal cells (21,22) is currently unknown. Among 
explanations proposed for the transdifferentiation of pancreas cells, a largely favored one in 
pathogenesis is based on the hypothesis that tumor stroma mimics the regulatory role of 
pancreatic embryonic mesenchyme in duct and endocrine development, to induce the switch 
between ductules and endocrine cells (23,24). A second hypothesis based on multiple lines of 
evidence also suggests that tumor cells may originate from a common pluripotent cell which 
matures into two phenotypically different cell lines (25), and this pluripotent cell expresses 
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transcription factors such as PDX1 and SOX9 which are involved in pancreatic development and 
homeostasis (26). Our study, which comprised of 369 pNEN cases and 3,277 healthy controls 
from the international PANDoRA consortium, represents the largest of such studies performed 
to date. Recent attempts to delineate the mutational landscape of pNENs through whole 
genome sequencing (6), have implicated activation of mTOR signaling as one of the core 
pathways commonly altered in these neoplasms.  
In overall risk analyses, four SNPs (rs9854771, rs9543325, rs1561927 and rs10919791) showed 
associations with sporadic pNEN at p<0.05. Adjustment for multiple comparisons was not 
applied to the nominal significance threshold (p<0.05) since selected SNPs were based on prior 
evidence of their association with pancreatic cancer. Using the FPRP model in overall analyses, 
only associations with rs10919791, rs9543325 and rs1561927 reached noteworthiness with a 
prior probability of 0.2. 
rs1561927 in MIR1208/PVT1 was associated with a 29% lower risk of developing pNEN among 
heterozygotes, which is similar to the original report in PDACs (allelic OR 0.87 95% CI (0.83–
0.92) (9)). This intronic SNP maps to a locus associated with suggested long-distance 
interactions with MYC and PVT1 promoters in multiple cancers (9). rs9543325, an intergenic 
SNP in chr13q22.1 which is frequently deleted in several cancers (8) was associated with a 37% 
increased risk of developing pNEN (for subjects with CC genotype), higher than risk estimates 
from the original study in PDACs (OR 1.26 95% CI (1.18–1.35) (8). Genes closest to this locus are 
KLF5, KLF12, PIBF1, DIS3 and BORA, which range up to 586kb in distance from rs9543325. 
Krüppel-like factor (KLF) 5 and 12 are members of a family of zinc-finger transcription factors 
reported to exhibit tumor-suppressor and oncogenic activity respectively in various human 
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cancers (27). KLF5 is involved in transcriptional activation of PI3K/Akt signaling, BORA (encoding 
aurora kinase A activator) is known to regulate cell proliferation and overexpressed in tumors 
(28). PIBF1 (encoding progesterone immunomodulatory binding factor 1) is speculated to be 
involved in progesterone-dependent immunomodulation with higher levels in tumors (28). 
Aberrant expression of DIS3 has been implicated in many cancers and plays a crucial role in 
gene regulation and small RNA processing (29). rs10919791 lies in the first intron of NR5A2 
(chr1q32.1) which plays crucial roles in pancreatic function and development (30). In the 
current study, rs10919791 was associated with a 35% lower risk of developing pNEN among 
heterozygotes, similar to the original estimate among PDACs (ORhet 0.76 (0.68–0.84)) (8).  
The bioinformatics approach with a GEO2R microarray dataset including pancreatic 
neuroendocrine tumors (n=6) and non-neoplastic pancreatic tissue samples (n=5), was used to 
augment results from our study and explore the plausible role of these genes in pNEN 
development. Interestingly, MYC, KLF5, NR5A2, CTRB1 and CTRB2 appeared down-regulated 
among pNENs compared to non-n oplastic pancreatic tissue in the microarray dataset, further 
implicating these genes in pNEN tumorigenesis. To substantiate these findings, we performed a 
similar comparison of xpression profiles of these genes in PDAC (n=6) versus healthy pancreas, 
which showed differential expression of all genes but KLF5 in the same manner.  To the best of 
our knowledge this is the only publicly available dataset that includes expression data of pNEN. 
The data we observed in this dataset corroborate our findings of the association analysis. 
Nevertheless the very small sample size of this dataset is a cause for concern, and these data 
should be taken with caution. 
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Additional stratified analyses based on age at onset and tumor characteristics (tables III and IV 
respectively), despite relatively small genotype strata for some SNPs, also shed light on 
susceptibility loci that may be useful for improved risk stratification and possible choice of 
therapy based on tumor characteristics. The contribution of rs7310409 to pNEN development is 
conceivable given that pleiotropic HNF1A plays a crucial role, as a tumor suppressor, in the 
transcriptional regulation in endocrine and exocrine pancreas development and homeostasis 
(31). This locus has also been reported as a prime candidate mediating susceptibility to type 2 
diabetes among Caucasians (32). Although the role of p53 homolog, p63 in pancreatic cancer is 
poorly understood, it has been implicated in tumorigenesis and metastasis via cell cycle arrest 
and apoptotic mechanisms (33). Our observed association between heterozygous carriers of 
this polymorphism and metastatic pNEN tumors is therefore plausible.  
Nevertheless, the small size observed in each stratum due to the rarity of these neoplasms, 
raises a valid concern on the possible interpretation of our findings. We therefore applied the 
FPRP approach instead of a much lower P value adjusted for multiple comparisons, as the latter 
would have resulted in unnecessarily low power for our high prior probability hypotheses, 
particularly in these n oplasms where collection of larger number of cases is unrealistic. 
Notwithstanding, all noteworthy findings reported here must be interpreted with caution and 
replicated in possibly larger and independent studies. 
The major strengths of this study are its relatively large size, considering the low incidence of 
pNEN, and data analysis approaches applied to minimize the effect of potentially confounding 
factors and more importantly evaluate the noteworthiness of our findings. The integration of 
gene expression profiling provides valuable insight to shared genetic correlations and expands 
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the probable margins of our results. A limitation of our investigations however, was that due to 
lack of clinical information, we could not stratify subjects based on familial history of PDAC or 
other non-genetic factors such as history of diabetes mellitus.  
Taken together, these results illuminate genetic similarities between the two main groups of 
pancreatic neoplasms, suggesting that common variations at three known PDAC susceptibility 
loci – 13q22.1 (TP63, rs9543325), 1q32.1 (NR5A2, rs10919791) and 8q24.21 (MIR1208/PVT1, 
rs1561927) potentially influence tumorigenesis of pancreatic beta cells in a similar manner as in 
exocrine pancreatic cells. Our results also suggest that genetic predisposing factors vary on the 
basis of age at pNEN onset as well as tumor characteristics. Striking similarities between 
embryogenesis and tumorigenesis which have become more apparent in past decades taken 
together with our genetic findings may provide groundwork for future evaluation of the 
potential usability of these loci as predictive biomarkers and in risk assessment. Functional 
studies are also warranted to better understand the biological implications of these loci in 
pancreatic hormone-producing (endocrine) and enzyme-producing (exocrine) cell function. 
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Table I. Clinical characteristics of cases and controls used in this study. 
Region of origin Germany Greece Italy Poland 
United 
Kingdom 
Total 
subjects* 
Median age at  
diagnosis†, y  
(1st-3rd quartile)  
51 
(44-58) 
45 
(35-58) 
61 
(49-72) 
46 
(31-66) 
66 
(59-74) 
57 
(44-67) 
 ≤50 y 383 151 491 237 15 1277 
 >50 y 394 75 1238 185 209 2101 
Gender 
 Males  356 135 1098 185 130 1906 
 Females 421 95 814 257 94 1681 
Functional status  
 yes 4 20 47 3 3 77 
 no n/a 2 118 3 n/a 123 
unknown 31 0 82 9 47 169 
Grade, G (WHO) 
 G1 and G2 n/a 21 149 9 29 208 
 G3 n/a 1 6 2 1 10 
unknown 35 0 12 4 20 71 
Stage (ENETS) 
 I / II / III 17 n/a 133 12 n/a 162 
 IV 5 n/a 32 2 n/a 39 
unknown 13 22 82 1 50 168 
Total cases 35 22 247 15 50 369 
Total controls 797 208 1670 427 175 3277 
Abbreviations: WHO = World Health Organization; ENETS = European Neuroendocrine Tumor Society; y 
= years; n/a = not available 
* Numbers may not add up to 100% due to genotyping failure or unavailable covariate data. 
† pNEN cases only
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Table II. Associations between known GWAS PDAC susceptibility loci and pNEN risk. 
SNP (nearby gene(s)) 
Genotypes 
(cases/controlsa) 
MAF CEU 
1KG / Current 
studyb 
MM vs Mmc MM vs mmc 
OR 
(95% CI) d 
P 
OR 
(95% CI) d 
P 
rs351365 (WNT2B) 
CC (198/1549) 
CT (108/938) 
TT (26/172) 
0.27/0.24 
0.91 
(0.69-1.20) 
0.50 
1.34 
(0.82-2.18) 
0.24 
rs3790844 (NR5A2) 
TT (140/1231) 
TC (64/721) 
CC (19/123) 
0.36/0.23 
0.82 
(0.59-1.13) 
0.22 
1.27 
(0.74-2.16) 
0.38 
rs1486134 (ETAA1) 
TT (162/1569) 
TG (141/1120) 
GG (31/217) 
0.27/0.27 
1.20 
(0.94-1.55) 
0.13 
1.36 
(0.88-2.09) 
0.16 
rs9854771 (TP63) 
GG (149/1131) 
GA (140/1311) 
AA (51/350) 
0.29/0.36 
0.76 
(0.58-0.99) 
0.04 
1.00 
(0.69-1.46) 
0.98 
rs2736098 (TERT) 
GG (158/1514) 
GA (130/1131) 
AA (19/211) 
0.27/0.27 
1.08 
(0.84-1.39) 
0.56 
0.84 
(0.50-1.41) 
0.51 
rs17688601 (SUGCT) 
AA (31/226) 
AC (130/1082) 
CC (176/1469) 
0.17/0.28 
0.98 
(0.77-1.26) 
0.89 
1.19 
(0.78-1.82) 
0.41 
rs6971499 (LINC-PINT) 
AA (241/2222) 
AG (67/755) 
GG (5/72) 
0.12/0.15 
0.85 
(0.64-1.14) 
0.27 
0.89 
(0.35-2.27) 
0.81 
rs167020 (SHH) 
AA (20/80) 
AG (108/392) 
GG (127/507) 
0.15/0.26 
1.04 
(0.68-1.59) 
0.85 
0.92 
(0.44-1.94) 
0.83 
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rs1561927 (MIR1208, PVT1) 
CC (25/238) 
CT (104/1297) 
TT (181/1643) 
0.30/0.28 
0.71 
(0.55-0.92) 
0.01 
0.91 
(0.58-1.43) 
0.69 
SNP (nearby gene(s)) 
Genotypes 
(cases/controlsa) 
MAF CEU 
1KG / Current 
studyb 
MM vs Mmc MM vs mmc 
OR 
(95% CI) d 
P 
OR 
(95% CI) d 
P 
rs10991043 (SMC2) 
CC (48/371) 
CT (146/1295) 
TT (133/1190) 
0.43/0.36 
1.02 
(0.79-1.31) 
0.90 
1.17 
(0.81-1.68) 
0.41 
rs505922 (ABO) 
TT (110/935) 
TC (120/1019) 
CC (28/333) 
0.35/0.39 
1.11 
(0.84-1.48) 
0.45 
0.76 
(0.48-1.19) 
0.23 
rs7310409 (HNF1A) 
GG (120/1008) 
GA (159/1409) 
AA (59/490) 
0.41/0.39 
0.90 
(0.69-1.16) 
0.41 
1.04 
(0.74-1.46) 
0.84 
rs9581943 (PDX1) 
GG (110/1016) 
GA (149/1524) 
AA (51/510) 
0.33/0.42 
0.94 
(0.72-1.22) 
0.64 
0.91 
(0.64-1.31) 
0.62 
rs9543325 
(KLF5/KLF12/PIBF1/DIS3/BORA) 
CC (48/316) 
CT (113/960) 
TT (62/771) 
0.46/0.39 
1.35 
(0.96-1.89) 
0.08 
1.63 
(1.10-2.47) 
0.02 
rs8028529 (None) 
TT (155/1194) 
TC (86/654) 
CC (16/106) 
0.20/0.22 
1.08 
(0.79-1.48) 
0.64 
1.25 
(0.69-2.25) 
0.46 
rs7190458 
(BCAR1/CTRB1/CTRB2) 
CC (294/2832) 
CT (18/215) 
TT (1/5) 
0.10/0.04 
0.78 
(0.46-1.30) 
0.34 
2.25 
(0.25-20.3) 
0.47 
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rs11655237 (LINC00673) 
CC (256/2113) 
CT (75/583) 
TT (3/37) 
0.23/0.12 
1.08 
(0.80-1.45) 
0.63 
0.70 
(0.16-3.02) 
0.64 
rs1517037 (GRP) 
CC (227/1871) 
CT (107/896) 
TT (10/129) 
0.24/0.20 
0.89 
(0.69-1.15) 
0.36 
0.59 
(0.30-1.15) 
0.12 
SNP (nearby gene(s)) 
Genotypes 
(cases/controlsa) 
MAF CEU 
1KG / Current 
studyb 
MM vs Mmc MM vs mmc 
OR 
(95% CI) d 
P 
OR 
(95% CI) d 
P 
rs16986825 (ZNRF3) 
CC (193/1996) 
CT (100/919) 
TT (15/108) 
0.20/0.19 
1.07 
(0.82-1.39) 
0.63 
1.21 
(0.67-2.17) 
0.53 
rs2853677 (TERT) 
AA (89/783) 
AG (155/1319) 
GG (52/532) 
0.39/0.45 
1.01 
(0.74-1.38) 
0.94 
0.82 
(0.54-1.22) 
0.32 
rs401681 (TERT) 
TT (51/377) 
TC (129/949) 
CC (76/649) 
0.41/0.43 
1.10 
(0.81-1.52) 
0.52 
1.11 
(0.75-1.63) 
0.61 
rs10919791 (NR5A2) 
GG (148/1272) 
GA (50/682) 
AA (15/111) 
0.35/0.22 
0.65 
(0.46-0.93) 
0.02 
1.06 
(0.59-1.90) 
0.84 
rs3790843 (NR5A2) 
GG (124/1064) 
GA (72/847) 
AA (25/178) 
0.40/0.29 
0.76 
(0.55-1.04) 
0.09 
1.20 
(0.74-1.93) 
0.46 
Abbreviations: MAF CEU = minor allele frequency in Caucasians; 1kG = 1000 Genomes Project (http://browser.1000genomes.org); OR = odds 
ratio; CI = confidence interval.  
Only association results for SNPs with P<0.05 and with outcomes below FPRP-level 0.2 are marked bold. 
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a Numbers may not add up to 100% due to genotyping failure or unavailable covariate data; b Controls only; c M - major allele, m - minor allele 
where MM represents the reference category.  
d Analyses were performed with adjustment for age, gender and country of origin.
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Table III. Associations between TERT_rs2736098, ZNF_rs16986825, rs9543325 and risk of pNEN 
onset. 
Locus Gene SNP ID 
Genotypes 
(Cases≤50y/>50y) 
OR (95% CI)a P 
5p15.33 TERT rs2736098 
GG (52/104) 
GA (36/89) 
AA (12/7) 
0.83 (0.50-1.40)† 
3.71 (1.36-10.10)* 
1.04 (0.64-1.69)¥ 
0.49 
0.01 
0.89 
22q12.1 ZNRF3 rs16986825 
CC (53/136) 
CT (46/52) 
TT (3/11) 
2.67 (1.57-4.55)† 
0.67 (0.17-2.63)* 
2.27 (1.37-3.77)¥ 
0.0003 
0.57 
0.002 
3q28 TP63 rs9854771 
GG (38/108) 
GA (53/87) 
AA (15/35) 
1.85 (1.11-3.10)† 
1.29 (0.63-2.66)* 
1.69 (1.04-2.75)¥ 
0.02 
0.49 
0.03 
Only association results for SNPs with P<0.05 and with outcomes below FPRP-level 0.2 are marked bold. 
a Cases only - ≤50 years (n=114) versus >50 years (n=247); where cases >50 years represent the 
reference category. Analyses were performed with adjustment for gender and country of origin. 
† MM vs Mm; * MM vs mm; ¥ (MM+Mm) vs mm; where M - major allele and m - minor allele; y= years. 
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Table IV. Associations between SNPs and pNEN tumor characteristics. 
Locus Gene SNP Genotype groups OR (95% CI)a P 
Grade (G1/G2/well differentiated tumors vs. G3/poorly differentiated tumors) 
1q32.1 NR5A2 rs10919791 
GG/GA/AA 
115/38/15 
5.66 (1.18-27.11)† 0.03 
22q12.1 ZNRF3 rs16986825 
CC/CT/TT  
113/62/9 
7.34 (1.02-52.67)* 
 7.44 (1.10-50.53)¥ 
0.05 
0.04 
Stage (I/II/III vs. IV) 
8q24.21 MIR1208, PVT1 rs1561927 
CC/TC/TT 
18/55/95 
2.39 (1.18-4.85)† 0.02 
3q28 TP63 rs9854771 
AA/GA/GG 
22/67/81 
0.44 (0.22-0.90)† 0.02 
1p13.1 WNT2B rs351365 
AA/GA/GG 
11/58/99 
4.15 (1.01-16.95)* 
4.62 (1.16-18.38)¥ 
0.05 
0.03 
Functional status (functional tumors vs. non-functional tumors) 
12q24.21 HNF1A rs7310409 
AA/GA/GG 
32/79/66 
0.36 (0.16-0.79)† 0.01 
18q21.2 GRP rs1517037 
CC/CT/TT 
118/56/4 
0.37 (0.16-0.85)† 0.02 
Only association results for SNPs with P<0.05 and with outcomes below FPRP-level 0.2 are marked bold. 
Analyses were performed with adjustment for age, gender and country of origin. 
a All G1 and G2 (i.e well-differentiated) tumors, non-functional tumors, and Stage I, II and III tumors (i.e. 
no nodal metastasis) represent the reference category for Grade, Functional status and Stage 
respectively. † MM vs Mm; * MM vs mm; ¥ (MM+Mm) vs mm; where M - major allele and m - minor 
allele 
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Table V. Differentially-expressed genes obtained from the GSE43795 dataset (6 pNEN tumors vs. 5 non-neoplastic pancreatic tissue 
samples and 6 pNEN tumors vs. 6 ductal adenocarcinoma tissues). 
Gene 
pNEN vs. normal PDAC vs. normal 
Log2 fold-change P Adjusted-P* Log2 fold-change P Adjusted-P* 
MYC 4.38 9.47x10-7 5.88x10-5 2.65 4.55x10-4 5.93x10-3 
NR5A2 4.91 7.82x10-10 2.38x10-7 3.51 2.00x10-4 3.31x10-3 
KLF5 1.69 1.59x10-2 6.96x10-2 -1.41 1.59x10-1 3.18x10-1 
CTRB1 7.90 1.10x10-9 3.04x10-7 7.55 2.56x10-8 5.18x10-6 
CTRB2 7.70 6.75x10-8 8.08x10-6 7.33 1.71x10-6 1.13x10-4 
PDX1 0.72 3.58x10-1 5.49x10-1 2.43 1.18x10-3 1.16x10-2 
* P-value adjusted using Benjamini & Hochberg method (False discovery rate) 
Based on predefined cutoff value of Adjusted-P < 0.05 and |log2 fold-change| > 1, genes which are differentially expressed in both groups are in 
bold. 
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